E3 PreliminaryPreliminaryPEM unclearObservationalPeer-reviewedMachine draft
Antibodies to Epstein-Barr virus-specific DNase and DNA polymerase in the chronic fatigue syndrome.
Jones, J F, Williams, M, Schooley, R T et al. · Archives of internal medicine · 1988
Quick Summary
This 1988 study tested whether people with ME/CFS had unusual antibody patterns against Epstein-Barr virus (EBV), a common virus that causes mononucleosis. Researchers measured antibodies against viral enzymes that are only produced when EBV is actively replicating. A small group of ME/CFS patients with very high EBV antibody levels did show these unusual enzyme antibodies, similar to patterns seen in people with nasopharyngeal cancer.
Why It Matters
This study provided early evidence that a subset of ME/CFS patients might have markers of persistent active EBV infection, potentially explaining some cases of the illness. The concerning observation of lymphoma development in patients with this specific antibody profile highlights the importance of identifying any subgroups at elevated cancer risk and understanding EBV's role in ME/CFS pathology.
Observed Findings
- Healthy EBV-seropositive controls neutralized mean ±SD of 3.5 ± 5.1 U of DNase and 14.7 ± 8.5 U of DNA polymerase activity.
- Only patients with very high anti-EBV VCA titers (>10,000) showed elevated anti-DNase (38–56 U) and anti-DNA polymerase (72–106 U) antibodies.
- These patients also had detectable IgA anti-VCA and anti-early antigen antibodies.
- Three of six patients with elevated anti-EBV enzyme antibody levels developed fatal lymphomas during follow-up.
Inferred Conclusions
- A subset of chronic EBV syndrome patients with notably elevated VCA titers and high anti-EBV enzyme antibody levels may have markers of active viral replication.
- The antibody profiles in these patients resemble those seen in nasopharyngeal carcinoma patients, suggesting potential oncologic risk.
- Patients with this specific EBV antibody profile may represent a distinct illness category with heightened risk for malignant disease.
Remaining Questions
- What proportion of the broader ME/CFS population exhibits this antibody pattern, and does it correlate with severity or prognosis?
- Is active EBV replication the primary cause or a secondary consequence of immune dysfunction in these patients?
- What is the true incidence of lymphoma in patients with this antibody profile, and are there preventive or monitoring strategies that should be implemented?
What This Study Does Not Prove
This small observational study cannot prove that active EBV infection causes ME/CFS, nor does it establish how common this antibody pattern is in the broader ME/CFS population. The observed lymphoma cases are anecdotal and do not demonstrate a causal link to the antibody profile. Correlation between antibody levels and illness does not establish causation or clarify whether viral replication is a primary driver or a consequence of immune dysfunction.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- PMID
- 2843138
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →